Einstellungen zur Einführung der psychedelischen Therapie

ZUSAMMENFASSUNG

In 11 Fokusgruppeninterviews diskutierten 31 Teilnehmende, gegliedert in die Zielgruppen Ärzte, Psychotherapeuten und (Ex-)Patienten ihre Einstellungen, Wünsche und Bedenken in Bezug auf die mögliche Einführung psychedelischer Therapien in das deutsche Gesundheitssystem. Folgende Themenbereiche wurden besprochen: Risiken und Potenziale psychedelischer Therapien; Erwartungen und Wünsche; Zulassung, Regulation und Zugänglichkeit; therapeutische Begleitung psychedelischer Therapien; Ausbildung zur Durchführung psychedelischer Therapien; Rahmenbedingungen und Durchführung psychedelischer Therapien; Sicherheitsvorkehrungen; vermutete Wirkfaktoren psychedelischer Therapien und Befürchtungen und Bedenken. Die Teilnehmenden äußerten sich größtenteils optimistisch und wünschten sich eine patientennahme und risikominimierende Regulierung psychedelischer Therapien.

ABSTRACT

In 11 focus group interviews, 31 participants, divided into the target groups of doctors, psychotherapists and (ex-)patients, discussed their attitudes, wishes and concerns regarding the possible implementation of psychedelic therapies into the German health care system. The following topics were discussed: Risks and potentials of psychedelic therapy; expectations and wishes; licensing, regulation and accessibility; therapeutic supervision of psychedelic therapy; training for conducting psychedelic therapy; conditions and implementation of psychedelic therapy; safety precautions; presumed effect factors of psychedelic therapy and fears and concerns. The participants were largely optimistic and requested a patient-centred and risk-minimising regulation of psychedelic therapies.

Schlüsselwörter

Psychedelische Therapy - Psilocybin - psilocybinassistierte Therapie - augmentierte Psychotherapie

Key words

Psychedelic therapy - psilocybin - psilocybin-assisted therapy - augmented psychotherapy

Publication History

Article published online:
11 June 2024

• Literatur

• 1 Gründer G, Jungaberle H. The Potential Role of Psychedelic Drugs in Mental Health Care of the Future. Pharmacopsychiatry 2021; 54: 191-199
• 2 van Amsterdam J, van den Brink W. The therapeutic potential of psilocybin: a systematic review. Expert Opinion on Drug Safety 2022; 21: 833-840
• 3 Dawood Hristova JJ, Pérez-Jover V. Psychotherapy with Psilocybin for Depression: Systematic Review. Behavioral Sciences 2023; 13: 297
• 4 Carhart-Harris R, Giribaldi B, Watts R. et al Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine 2021; 384: 1402-1411
• 5 Goldberg SB, Pace BT, Nicholas CR. et al The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis. Psychiatry Research 2020; 284: 112749
• 6 Garcia-Romeu A, Griffiths R, Johnson M. Psilocybin-Occasioned Mystical Experiences in the Treatment of Tobacco Addiction. Current Drug Abuse Reviews 2014; 07: 157-164
• 7 Smith KW, Sicignano DJ, Hernandez AV. et al MDMA-Assisted Psychotherapy for Treatment of Posttraumatic Stress Disorder: A Systematic Review With Meta-Analysis. The Journal of Clinical Pharmacology 2022; 62: 463-471
• 8 Mertens LJ, Koslowski M, Betzler F. et al Methodological challenges in psychedelic drug trials: Efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE) – Rationale and study design. Neuroscience Applied 2022; 01: 100104
• 9 Schmidt C, Wolff M, Gründer G.. et al Einstellungen von Expertinnen und Experten für psychische Gesundheit gegenüber Psilocybin. Fortschr Neurol Psychiatr 2022
• 10 Barnett BS, Siu WO, Pope HG. A Survey of American Psychiatrists’ Attitudes Toward Classic Hallucinogens. J Nerv Ment Dis 2018; 206: 476-480
• 11 Hearn BG, Brubaker MD, Richardson G. Counselors’ attitudes toward psychedelics and their use in therapy. Journal of Counseling & Development 2022; 100: 364-373
• 12 Davis AK, Agin-Liebes G, España M. et al Attitudes and Beliefs about the Therapeutic Use of Psychedelic Drugs among Psychologists in the United States. Journal of Psychoactive Drugs 2022; 54: 309-318
• 13 Wolff M.. et al Measuring Psychotherapeutic Processes in the Context of Psychedelic Experiences: Validation of the General Change Mechanisms Questionnaire (GCMQ). Journal of Psychopharmacology akzeptiert
• 14 Corrigan K, Haran M, McCandliss C. et al Psychedelic perceptions: mental health service user attitudes to psilocybin therapy. Ir J Med Sci 2022; 191: 1385-1397
• 15 Page LA, Rehman A, Syed H. et al The Readiness of Psychiatrists to Implement Psychedelic-Assisted Psychotherapy. Front Psychiatry 2021; 12: 743599
• 16 Reynolds LM, Akroyd A, Sundram F. et al Cancer Healthcare Workers’ Perceptions toward Psychedelic-Assisted Therapy: A Preliminary Investigation. International Journal of Environmental Research and Public Health 2021; 18: 8160
• 17 Beaussant Y, Sanders J, Sager Z. et al Defining the Roles and Research Priorities for Psychedelic-Assisted Therapies in Patients with Serious Illness: Expert Clinicians’ and Investigators’ Perspectives. Journal of Palliative Medicine 2020; 23: 1323-1334
• 18 Goodwin GM, Malievskaia E, Fonzo GA. et al Must Psilocybin Always “Assist Psychotherapy”? AJP. 2023 appi.ajp.20221043
• 19 Gründer G, Brand M, Mertens LJ.. et al Treatment with psychedelics is psychotherapy: beyond reductionism. The Lancet Psychiatry. 2023
• 20 Zoom Video Communications, Inc. (2023). Zoom (15.16.2) [Software]. Zoom Video Communications https://zoom.us/
• 21 Adobe Inc. (2023). Adobe Premiere Pro (23.6) [Software]. Adobe Inc https://www.adobe.com/products/premiere.html
• 22 MAXQDA [Computer software]. (2023). VERBI Software. Retrieved from https://www.maxqda.com/
• 23 Mayring P.. Qualitative Inhaltsanalyse: Grundlagen und Techniken. Weinheim: Dt. Studien-Verlag; 1997
• 24 Braun V, Clarke V. Using thematic analysis in psychology. Qualitative Research in Psychology 2006; 03: 77-101
• 25 Artin H, Zisook S, Ramanathan D. How do serotonergic psychedelics treat depression: The potential role of neuroplasticity. World J Psychiatry 2021; 11: 201-214